<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101120777</journal-id>
<journal-id journal-id-type="pubmed-jr-id">27010</journal-id>
<journal-id journal-id-type="nlm-ta">Expert Rev Mol Diagn</journal-id>
<journal-id journal-id-type="iso-abbrev">Expert Rev. Mol. Diagn.</journal-id>
<journal-title-group>
<journal-title>Expert review of molecular diagnostics</journal-title>
</journal-title-group>
<issn pub-type="ppub">1473-7159</issn>
<issn pub-type="epub">1744-8352</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26489042</article-id>
<article-id pub-id-type="pmc">4955806</article-id>
<article-id pub-id-type="doi">10.1586/14737159.2015.1101348</article-id>
<article-id pub-id-type="manuscript">NIHMS798030</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Advanced technologies for the molecular diagnosis of fragile X syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Tassone</surname>
<given-names>Flora</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Biochemistry and Molecular Medicine, University of California, Davis, School of Medicine, Davis, California 95616, USA</aff>
<aff id="A2"><label>2</label>MIND Institute, University of California Davis Medical Center, Sacramento, California 95817, USA</aff>
<author-notes>
<corresp id="cor1">Tel: (916) 703-0463, FAX: (916) 703-0464, <email>ftassone@ucdavis.edu</email></corresp>
<fn id="FN1">
<p id="P1">
<bold>Dedication</bold>
</p>
<p id="P2">This work is dedicated to the memory of Matteo.</p>
</fn>
<fn fn-type="conflict" id="FN2">
<p id="P29">
<bold>Financial &amp; competing interests disclosure</bold>
</p>
<p id="P30">The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>13</day>
<month>7</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>21</day>
<month>10</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2015</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>21</day>
<month>10</month>
<year>2016</year>
</pub-date>
<volume>15</volume>
<issue>11</issue>
<fpage>1465</fpage>
<lpage>1473</lpage>
<!--elocation-id from pubmed: 10.1586/14737159.2015.1101348-->
<abstract>
<p id="P3">Fragile X syndrome (FXS), a trinucleotide repeat disorder, is the most common heritable form of cognitive impairment. Since the discovery of the <italic>FMR1</italic> gene in 1991, great strides have been made in the field of molecular diagnosis for FXS. Cytogenetic analysis, which was the method of diagnosis in the early 1990, was replaced by Southern blot and PCR analysis albeit with some limitations. In the past few years many PCR-based methodologies, able to amplify large full mutation expanded alleles, with or without methylation, have been proposed. Reviewed here are the advantages, disadvantages and limitations of the most recent developments in the field of FXS diagnosis.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>